Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement
Lorigan, Paul C
AffiliationLeeds Teaching Hospitals NHS Trust, United Kingdom
MetadataShow full item record
AbstractSentinel node biopsy (SNB) has been at the forefront of the surgical staging of melanoma patients for the past 15 years. The high accuracy of this prognostic staging procedure is now recognised in all international guidelines for melanoma. However during this period there have been a number of important changes in the management of melanoma, many occurring within the past five years. The outcomes of five recent randomised Phase 3 trials have established the role of adjuvant targeted therapy and immunotherapy in resected Stage 3 and Stage 4 disease and have potentially changed the role of SNB. Two landmark international prospective studies have examined the benefit of performing a completion lymph node dissection (CLND) following the detection of microscopicallyinvolved sentinel nodes. Finally, the marked increase in the incidence of melanoma and the role of SNB in potentially guiding therapy has resulted in a significant increase in the pathological workload of the dermatopathology services. To address these issues a multi-disciplinary consensus meeting involving many melanoma experts from the UK was convened in May 2018. Three main areas were considered: oncology, surgery and pathology. This report is a summary of the conclusions reached, which were agreed by the clinicians attending the meeting and then externally peer reviewed. The recommendations summarised in this Consensus Statement.
CitationPeach H, Board R, Cook M, Corrie P, Ellis S, Geh J, et al. Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement. J Plast Reconstr Aesthet Surg. 2020;73(1):36-42.
JournalJournal of Plastic Reconstructive and Aesthetic Surgery
- Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
- Authors: Eggermont AM
- Issue date: 2000
- Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.
- Authors: McMasters KM, Egger ME, Edwards MJ, Ross MI, Reintgen DS, Noyes RD, Martin RC 2nd, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Sussman JJ, Davidson BS, Gershenwald JE, Hagendoorn LJ, Stromberg AJ, Scoggins CR
- Issue date: 2016 Apr 1
- [Stage III melanoma: Sentinel node biopsy, completion lymph node dissection and prospects of adjuvant therapy. A French national survey on current and envisaged practices].
- Authors: Orion C, Dinulescu M, Dalac-Rat S, Giacchero D, Jouary T, Lebbé C, Leccia MT, Maubec E, Meyer N, Mortier L, Dupuy A, Groupe de cancérologie cutanée de la Société française de dermatologie.
- Issue date: 2020 Jan
- The role of sentinel lymph-node biopsy in the management of cutaneous melanoma.
- Authors: Crowson AN, Haskell H
- Issue date: 2013 Oct
- Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma.
- Authors: Doubrovsky A, De Wilt JH, Scolyer RA, McCarthy WH, Thompson JF
- Issue date: 2004 Sep